SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-Q/A
Amendment No. 1 to the Quarterly Report pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934 for the quarterly period ended September 30,1996
Commission File Number 0-24760
ORPHAN MEDICAL, INC.
(Exact name of registrant as specified in its charter)
Minnesota 41-1784594
(State of other jurisdiction of (I.R.S. Employer Identification Number)
incorporation or organization)
13911 Ridgedale Drive, Suite 475,
Minnetonka, MN 55305 (612) 513-6900
(Address of principal executive (Registrant's telephone number,
offices and zip code) including area code)
STATEMENT TO BE INCLUDED IN THE FORM 10-Q
The purpose of this amendment No. 1 to Form 10-Q, filed by Orphan
Medical, Inc. on November 8, 1996, is to amend the Exhibit Index to reflect that
portions of Exhibit Number 10.40 have been omitted pursuant to a request for
confidential treatment. The page containing the amended Exhibit Index is
included in this Form 10-Q/A.
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
EXHIBIT INDEX
Exhibit Sequentially
Number Description Numbered Page
10.40 Cystadane Agreement between the Company and 13
Chronimed dated October 11, 1996 (NOTE:
PORTIONS OF THE EXHIBIT HAVE BEEN
OMITTED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT)
27 Financial Data Schedule -- For SEC EDGAR Filing 22
99 Cautionary Statements 23
(b) Reports on Form 8-K
No reports on Form 8-K were filed during the quarter ended September 30, 1996.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Orphan Medical, Inc.
---------------------------
Registrant
Date: December 3, 1996 /s/ David A. Feste
--------------------------- ---------------------------
David A. Feste
Chief Financial Officer
(principal accounting
officer and principal
financial officer)
